Interviews

Mark Metersky, MD, discussed heterogeneity, pathogens, and precision approaches in community-acquired pneumonia care.

Jamie R. Felzer, MD, discussed emerging vaccine strategies, preventive care, and translating evolving evidence into pulmonary practice at ATS 2026.

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know about managing infections and CRS.

Yet Khor, MD, PhD, highlights diagnostic delays, language barriers, and inequities impacting ILD and PF care access.

Adam Kittai, MD, weighs the favorable safety profile of acalabrutinib plus venetoclax against lingering unknowns on long-term efficacy and high-risk patients.

Breast cancer incidence climbs in young women under 40 and risk-based screening earlier may help reduce this, explains Rani Bansai, MD.

Kirk Campbell, MD, discusses why FSGS is traditionally difficult to treat, the significance of the sparsentan approval, and future access needs.

Kirk Campbell, MD, sees sparsentan as the beginning of a new treatment era for FSGS, a condition that has lacked approved therapies until now.

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

SUNRISE trial data showed tezepelumab reduced oral steroid use while maintaining asthma control in severe asthma.

Research done by Anton Kolomeyer, MD, PhD, showed increasing prescription of opioid medication after ocular surgery.

PASSAGE trial data showed tezepelumab reduced asthma exacerbations in diverse and underrepresented patient populations, noted Njira L. Lugogo, MD.

ATS 2026 findings highlighted bleeding risks and hemodynamic responses with sotatercept in CTD-associated pulmonary arterial hypertension (PAH).

RECOVER Initiative findings highlighted the heterogeneity of long COVID symptoms and mechanisms in diverse patient populations.

PASSAGE study data showed tezepelumab improved asthma outcomes across diverse, underrepresented patient populations.

Community oncology can navigate bispecific therapy rollout with staff training, clear handoffs, and reliable reimbursement, said Lekan Ajayi, PharmD.

The Supreme Court’s temporary action on mifepristone telehealth access raises new questions about reproductive health policy, autonomy, and care access in the US.

Community oncology grapples with the logistics of bispecifics with step-up dosing straining staff and reimbursement, said Lekan Ajayi, PharmD.

Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.

Deborah Doroshow, MD, PhD, discusses lung cancer trial access, targeted therapy advances, and treatment gaps in part 2 of her interview.

Scott Shannon, MD, discusses psychedelic therapies, federal policy shifts, and the barriers slowing mental health innovation.

Muhammad Bilal Abid, MD, discusses COVID-19 variant surveillance, monoclonal antibodies, and layered prevention in immunocompromised patients.

Community pharmacists must build scalable workflows as bispecific antibodies move into earlier lines and outpatient settings, notes Brooke Peters, PharmD, BCOP, of AON.

Deborah Doroshow, MD, PhD, blends oncology and history of medicine to guide cancer care, emphasizing communication, trust, and health equity.

Deborah Doroshow, MD, PhD, an oncologist and historian, reflects on guiding patients through cancer care and how lessons from the past shape treatment today.